Biomarin Pharmaceutical (BMRN) Capital Expenditures (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Capital Expenditures data on file, last reported at $20.9 million in Q1 2026.

• Quarterly Capital Expenditures rose 24.78% year-over-year to $20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.2 million (up 40.88% YoY) and the FY2025 annual result came in at $103.0 million, up 20.62% from the prior year.
• Capital Expenditures eased to $20.9 million in Q1 2026, from $40.7 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $133.1 million in Q4 2022 to a low of -$38.0 million in Q2 2022.
• A 5-year average of $21.3 million and a median of $20.9 million in 2026 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures plunged 510.85% — and 2023, when it jumped 2178.17%.
• Tracing BMRN's Capital Expenditures over 5 years: stood at $133.1 million in 2022, then plunged by 127.52% to -$36.6 million in 2023, then surged by 153.32% to $19.5 million in 2024, then surged by 108.51% to $40.7 million in 2025, then plunged by 48.62% to $20.9 million in 2026.
• The last three Capital Expenditures figures came in at $20.9 million (Q1 2026), $40.7 million (Q4 2025), and $48.8 million (Q3 2025), per Business Quant data.